Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Marco Del Chiaro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9614-6466; OpenAlex author ID A5045461482, A5103016182. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
105
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 3 papers · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 4 papers · 2025: 1 paper · 2026: 3 papers

Papers 25

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  2. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. Last author DOI 10.1016/j.hpb.2025.10.004↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  5. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2024.100070↗
  6. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  7. Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemothera… Last author DOI 10.1245/s10434-024-15443-1↗
  8. Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection. Co-author DOI 10.1245/s10434-024-15975-6↗
  9. Author Correction: Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cance… Last author DOI 10.1038/s41598-022-08527-z↗
  10. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hpb.2018.07.017↗
  11. Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.09.005↗
  12. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. Co-author DOI 10.1038/s41416-018-0262-z↗
  13. Radiological assessment of local resectability status in patients with pancreatic cancer: Interreader agreement and reader performance in two different classif… Co-author DOI 10.1016/j.ejrad.2018.06.014↗
  14. Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses. Co-author DOI 10.18632/oncotarget.25121↗
  15. Multidetector CT of pancreatic ductal adenocarcinoma: Effect of tube voltage and iodine load on tumour conspicuity and image quality. Co-author DOI 10.1007/s00330-016-4273-y↗
  16. Diffusion-weighted MR imaging of pancreatic cancer: A comparison of mono-exponential, bi-exponential and non-Gaussian kurtosis models. Co-author DOI 10.1016/j.ejro.2016.04.002↗
  17. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer. Co-author DOI 10.1097/cji.0000000000000111↗
  18. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2014.3852↗
  19. Pancreatic cancer. First author DOI 10.1155/2015/809036↗
  20. Is intraductal tubulopapillary neoplasia a new entity in the spectrum of familial pancreatic cancer syndrome? Co-author DOI 10.1007/s10689-013-9696-x↗
  21. Early detection and prevention of pancreatic cancer: is it really possible today? Co-author DOI 10.3748/wjg.v20.i34.12118↗
  22. "PancPro" as a tool for selecting families eligible for pancreatic cancer screening: an Italian study of incident cases. Last author DOI 10.1016/j.dld.2011.12.019↗
  23. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Co-author DOI 10.1093/annonc/mdq686↗
  24. Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pa… Co-author DOI 10.1159/000322990↗
  25. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Co-author DOI 10.1586/erm.11.62↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toshitaka Sugawara · 3 shared papers, 2024–2026 · strength 0.66
  2. Oskar Franklin · 3 shared papers, 2024–2026 · strength 0.66
  3. Richard David Schulick · 3 shared papers, 2024–2026 · strength 0.66
  4. Elena B. Rangelova · 5 shared papers, 2016–2026 · strength 0.54
  5. Carlos Fernández Moro · 4 shared papers, 2019–2024 · strength 0.51
  6. Matthias J. Löhr · 5 shared papers, 2015–2024 · strength 0.45
  7. Nikolaos Kartalis · 5 shared papers, 2015–2024 · strength 0.43
  8. Caroline Sophie Verbeke · 6 shared papers, 2014–2019 · strength 0.40
  9. Martin M. McCarter · 2 shared papers, 2024 · strength 0.39
  10. Robert J. Torphy · 2 shared papers, 2024 · strength 0.39
  11. Elliott J. Yee · 2 shared papers, 2024 · strength 0.39
  12. Roberto Salvia · 2 shared papers, 2024–2026 · strength 0.35
  13. Asif Halimi · 2 shared papers, 2019–2026 · strength 0.32
  14. Johanna Laukkarinen · 2 shared papers, 2015–2026 · strength 0.30
  15. Raffaella Pozzi Mucelli · 3 shared papers, 2014–2024 · strength 0.29
  16. Jun Ishida · 1 shared paper, 2026 · strength 0.28
  17. Samuele Grandi · 1 shared paper, 2026 · strength 0.28
  18. Andrii Khomiak · 1 shared paper, 2026 · strength 0.28
  19. Thomas F. Stoop · 1 shared paper, 2026 · strength 0.28
  20. Hiroyuki Ishida · 1 shared paper, 2026 · strength 0.28
  21. Massimo Falconi · 2 shared papers, 2012–2026 · strength 0.26
  22. Urban Arnelo · 2 shared papers, 2019–2022 · strength 0.23
  23. Roberto Valente · 2 shared papers, 2019–2022 · strength 0.23
  24. Giuseppe Malleo · 1 shared paper, 2026 · strength 0.22
  25. Giulio Belfiori · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.